Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,413 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
OASIS-3 is a compilation of MRI and PET imaging and related clinical data for 1098 participants who were collected across several ongoing studies in the Washington University Knight Alzheimer Disease Research Center over the course of 15 years.
Why it matters
OASIS-3 brings together MRI, PET and clinical data on 1,098 people aged 42 to 95 (605 cognitively normal, 493 at various stages of cognitive decline), collected over 15 years across several studies at Washington University's Knight Alzheimer Disease Research Center. It includes more than 2,000 MRI sessions, more than 1,500 amyloid and metabolic PET scans, and ready-processed measurements such as brain-volume segmentations. It is a shared research resource, not a test of any treatment, and on its own it does not show what causes or changes Alzheimer's.
-
Although large numbers of microRNAs (miRNAs) expressed in Alzheimer disease (AD) have been detected, their functions and mechanisms of regulation remain to be fully clarified.
Why it matters
This work found that miR-124 levels decrease in Alzheimer's disease and that miR-124 suppresses BACE1 expression by targeting Bace1 mRNA in vitro. This is laboratory work on a possible mechanism and does not establish a treatment for patients.
-
Alzheimer's disease (Alzheimer's), an ultimately fatal form of dementia, is the sixth leading cause of death in the United States, accounting for 3.6% of all deaths in 2014 (1,2).
Why it matters
US Alzheimer's deaths rose 54.5% between 1999 and 2014, and more people died at home rather than in medical facilities. The report notes this likely added to the burden on unpaid caregivers, who might benefit from support interventions.
-
Alzheimer’s disease (AD) is the most commonly occurring form of dementia.
Why it matters
This systematic review and economic model updated guidance on the clinical effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease. It reviews existing treatments for symptoms and does not report a cure or way to prevent the disease.
-
Directed conversion of mature human cells, as from fibroblasts to neurons, is of potential clinical utility for neurological disease modeling as well as cell therapeutics.
Why it matters
Skin fibroblasts from unaffected individuals and Alzheimer's patients were converted into neuron-like cells, and cells from familial Alzheimer's patients with presenilin mutations showed altered amyloid precursor protein processing and increased beta-amyloid production. This is a laboratory cell-modeling study and does not provide a treatment or cure.
-
A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease (AD), who are prone to falls and have osteoporosis.
Why it matters
In this trial of 231 elderly patients with Alzheimer's disease, treatment with menatetrenone, risedronate, and calcium reduced the relative risk of nonvertebral fractures, including hip fractures. This treatment addresses fracture prevention in people with Alzheimer's disease, not the disease itself.
-
Elderly patients with AD hypovitaminosis D are at increased risk for hip fracture.
Why it matters
In this 18-month trial of 500 elderly women with Alzheimer's disease, risedronate plus vitamin D and calcium reduced the risk of fractures, including hip fractures. This treatment addresses fracture prevention in these patients and does not treat, cure, or prevent Alzheimer's disease itself.
-
The EMA's human medicines committee (CHMP) initially refused to approve lecanemab in the EU in July 2024, judging that its modest effect on cognitive decline did not outweigh ARIA risk in the broad early-Alzheimer's population studied.
Why it matters
The EMA committee initially refused to approve lecanemab in the EU, judging its modest cognitive benefit did not outweigh ARIA risk, then reversed course and recommended approval limited to people with one or no copies of the ApoE4 gene. Approval was conditioned on an EU-wide safety registry and mandatory MRI scans before treatment and before doses 5, 7, and 14.
-
The FDA approved donanemab (Kisunla) as a monthly IV infusion for people with early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia) with confirmed amyloid plaques.
Why it matters
Donanemab was approved for early symptomatic Alzheimer's disease based on a trial of 1,736 patients showing statistically significant slowing of clinical decline through week 76. Like other anti-amyloid drugs, it carries a boxed warning for ARIA, with higher incidence in ApoE ε4 homozygotes.
-
The FDA gave lecanemab (Leqembi) accelerated approval based on Phase 2 data showing it reduced amyloid plaque in the brain, ahead of full Phase 3 results.
Why it matters
Lecanemab received accelerated approval based on Phase 2 data showing it reduced amyloid plaque, ahead of full Phase 3 results, with a warning about ARIA including brain swelling in 10% of treated patients versus 1% on placebo. Full approval was contingent on the Phase 3 Clarity AD trial confirming real clinical benefit.
-
The FDA converted lecanemab (Leqembi) from accelerated to full traditional approval after the Phase 3 Clarity AD trial (1,795 patients) confirmed it slowed cognitive decline, making it the first amyloid-targeting antibody to reach full approval for Alzheimer's. The drug carries a boxed warning for ARIA, brain swelling or bleeding that is usually detected on routine MRI and is more common in people with two copies of the ApoE ε4 gene or those on blood thinners.
Why it matters
Lecanemab became the first amyloid-targeting antibody converted to full traditional approval after the Phase 3 Clarity AD trial confirmed it slowed cognitive decline. It carries a boxed warning for ARIA, which is more common in people with two copies of the ApoE ε4 gene or those on blood thinners.
-
On January 31, 2024, Biogen announced it would discontinue development and sales of Aduhelm (aducanumab) and end the mandatory post-approval ENVISION confirmatory trial, redirecting resources to lecanemab (Leqembi) and other pipeline drugs, including two tau-targeting compounds (BIIB080, BIIB113).
Why it matters
Biogen discontinued Aduhelm and ended the FDA-mandated ENVISION confirmatory trial, stating the decision was not driven by new safety or efficacy concerns but by cost and lack of commercial partners. Resources were redirected to lecanemab and to tau-targeting candidates BIIB080 and BIIB113.
-
CMS's national policy covers FDA-approved anti-amyloid monoclonal antibodies (such as lecanemab and donanemab) for Medicare patients with a documented diagnosis of mild cognitive impairment or mild Alzheimer's dementia and confirmed amyloid pathology, under a framework called 'Coverage with Evidence Development.'
Why it matters
CMS covers FDA-approved anti-amyloid monoclonal antibodies for Medicare patients with mild cognitive impairment or mild Alzheimer's dementia and confirmed amyloid pathology, but only under Coverage with Evidence Development requiring participation in a qualifying registry. Use outside an FDA-approved trial, a CMS-approved registry, or an NIH-supported study is not covered nationally.
From across this topic
10 of the 5,374 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- 2009 Alzheimer's disease facts and figures
- Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia?
- Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease
- Association of Intracranial Atherosclerotic Disease With Brain β-Amyloid Deposition: Secondary Analysis of the ARIC Study
- Cost-effectiveness of testing biofluid biomarkers to diagnose Alzheimer's disease: a systematic review
- The potential role of nutritional components in improving brain function among patients with Alzheimers disease: a meta-analysis of RCT studies
- A Deep Siamese Convolution Neural Network for Multi-Class Classification of Alzheimer Disease
- The role of built and social environments in Alzheimer's disease dementia prevalence in the United States: A machine learning approach
- Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease
- Potential Role of Lymphovenous Bypass in Mitigating Alzheimer's Disease Dementia